Kontrastmittelgabe bei Niereninsuffizienz – praktische Handlungsempfehlungen

Zusammenfassung

Noch immer sorgt die Kontrastmittelgabe bei Patienten mit Niereninsuffizienz für regelmäßige Diskussionen im klinischen Alltag. Sowohl Röntgen- als auch MR-Kontrastmittel werden überwiegend renal eliminiert und sind somit eng an die Nierenfunktion gekoppelt. Basis der Risikostratifizierung vor Kontrastmittelgabe ist die Bestimmung der eGFR. Patienten mit einer eGFR ≥ 30 ml/min benötigen eine individuelle Risikobeurteilung. Bei fortgeschrittener Niereninsuffizienz liegt das Hauptaugenmerk auf der Gewährleistung der Euvolämie. Evidenz für anderweitige Präventionsansätze findet sich aktuell nicht, weitere spezifische Maßnahmen zur Prävention einer Kontrastmittel-assoziierten Nierenschädigung sind bei heutigen Kontrastmitteln somit nicht angezeigt. Eine zeitliche Abstimmung von Kontrastmittelgabe und Dialysesitzung bei terminaler Niereninsuffizienz ist nur nach Kontrastmittel-gestützten MRT-Untersuchungen zu beachten. Eine Sonderrolle stellt nach wie vor die akute Nierenschädigung dar.

Abstract

Contrast media use in patients with renal disease regularly ensures discussions in everyday clinical practice. Both X-ray and MRI contrast media are predominantly eliminated by the kidneys and therefore closely linked to kidney function. Risk stratification prior to contrast media use in patients with pre-existing renal dysfunction should be based on eGFR-determination. Patients with an eGFR ≥ 30 ml/min require an individual risk assessment. In patients with advanced renal insufficiency ensuring euvolemia is crucial. Currently, there is no evidence for any other preventive approach. Therefore, no further specific procedures preventing contrast-associated kidney injury are recommended. Timing of contrast media injection and dialysis sessions in patients with end stage renal disease is necessary only after MRI contrast media use. Independently, acute kidney injury requires a patient individual decision.

Schlüsselwörter

Kontrastmittel - Niereninsuffizienz - Kontrastmittel-Nephropathie - Gadolinium - Iod-haltig

Key words

contrast media - kidney disease - contrast induced nephropathy - gadolinium - iodine

Publikationsverlauf

Artikel online veröffentlicht:
05. November 2021

• Literatur

• 1 Jahn M, Becker S, Kribben A. Nierenfunktion bei kontrastmittelverstärkter Bildgebung. Nephrologe 2018; 13: 251-261 DOI: 10.1007/s11560-018-0261-3.
• 2 Deutsche Herzstiftung. Deutscher Herzbericht. 2017 2017.
• 3 Girndt M, Trocchi P, Scheidt-Nave C. et al. The Prevalence of Renal Failure. Results from the German Health Interview and Examination Survey for Adults, 2008-2011 (DEGS1). Dtsch Arztebl Int 2016; 113: 85-91 DOI: 10.3238/arztebl.2016.0085.
• 4 Ebert N, Jakob O, Gaedeke J. et al. Prevalence of reduced kidney function and albuminuria in older adults: the Berlin Initiative Study. Nephrol Dial Transplant 2017; 32: 997-1005 DOI: 10.1093/ndt/gfw079.
• 5 Toprak O. What is the best definition of contrast-induced nephropathy?. Ren Fail 2007; 29: 387-388 DOI: 10.1080/08860220701189843.
• 6 Latus J, Schwenger V, Schlieper G. et al. Kontrastmittelinduzierte akute Nierenschädigung – Konsensuspapier der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. und der Deutschen Gesellschaft für Nephrologie e. V. Der Internist 2021; 62: 111-120 DOI: 10.1007/s00108-020-00938-2.
• 7 McDonald RJ, McDonald JS, Bida JP. et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?. Radiology 2013; 267: 106-118 DOI: 10.1148/radiol.12121823.
• 8 KDIGO. Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements 2012; 2 DOI: 10.1038/kisup.2012.1.
• 9 Davenport MS, Perazella MA, Yee J. et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020; 294: 660-668 DOI: 10.1148/radiol.2019192094.
• 10 ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. 2021
• 11 van der Molen AJ, Reimer P, Dekkers IA. et al. Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018; 28: 2845-2855 DOI: 10.1007/s00330-017-5246-5.
• 12 Davenport MS, Khalatbari S, Cohan RH. et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 2013; 268: 719-728 DOI: 10.1148/radiol.13122276.
• 13 Subramaniam RM, Suarez-Cuervo C, Wilson RF. et al. Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 406-416 DOI: 10.7326/M15-1456.
• 14 Cruz DN, Goh CY, Marenzi G. et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 2012; 125: 66-78.e3 DOI: 10.1016/j.amjmed.2011.06.029.
• 15 Putzu A, Boscolo Berto M, Belletti A. et al. Prevention of Contrast-Induced Acute Kidney Injury by Furosemide With Matched Hydration in Patients Undergoing Interventional Procedures: A Systematic Review and Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv 2017; 10: 355-363 DOI: 10.1016/j.jcin.2016.11.006.
• 16 van der Molen AJ, Reimer P, Dekkers IA. et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018; 28: 2856-2869 DOI: 10.1007/s00330-017-5247-4.
• 17 Weisbord SD, Gallagher M, Jneid H. et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med 2018; 378: 603-614 DOI: 10.1056/NEJMoa1710933.
• 18 Nijssen EC, Rennenberg RJ, Nelemans PJ. et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. The Lancet 2017; 389: 1312-1322 DOI: 10.1016/S0140-6736(17)30057-0.
• 19 Nijssen EC, Nelemans PJ, Rennenberg RJ. et al. Evaluation of Safety Guidelines on the Use of Iodinated Contrast Material: Conundrum Continued. Invest Radiol 2018; 53: 616-622
• 20 European Society of Urogenital Radiology. Contrast Media Safety Guidelines 10.0. Im Internet (Stand: 21.04.2021): http://www.esur.org/fileadmin/content/2019/ESUR_Guidelines_10.0_Final_Version.pdf
• 21 Kooiman J, Le Haen PA, Gezgin G. et al. Contrast-induced acute kidney injury and clinical outcomes after intra-arterial and intravenous contrast administration: risk comparison adjusted for patient characteristics by design. Am Heart J 2013; 165: 793-799, e1 DOI: 10.1016/j.ahj.2013.02.013.
• 22 McDonald JS, Leake CB, McDonald RJ. et al. Acute Kidney Injury After Intravenous Versus Intra-Arterial Contrast Material Administration in a Paired Cohort. Invest Radiol 2016; 51: 804-809 DOI: 10.1097/RLI.0000000000000298.
• 23 Schönenberger E, Martus P, Bosserdt M. et al. Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial. Radiology 2019; 292: 664-672 DOI: 10.1148/radiol.2019182220.
• 24 Deray G. Dialysis and iodinated contrast media. Kidney International 2006; 69: S25-S29 DOI: 10.1038/sj.ki.5000371.
• 25 Oloko A, Talreja H, Davis A. et al. Does Iodinated Contrast Affect Residual Renal Function in Dialysis Patients? A Systematic Review and Meta-Analysis. Nephron 2020; 144: 176-184 DOI: 10.1159/000505576.
• 26 Bahrainwala JZ, Leonberg-Yoo AK, Rudnick MR. Use of Radiocontrast Agents in CKD and ESRD. Semin Dial 2017; 30: 290-304 DOI: 10.1111/sdi.12593.
• 27 Alscher MD, Erley C, Kuhlmann MK. Acute Renal Failure of Nosocomial Origin. Dtsch Arztebl Int 2019; 116: 149-158 DOI: 10.3238/arztebl.2019.0149.
• 28 Becker S, Walter S, Witzke O. et al. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis. Nephron Clin Pract 2012; 121: c91-c94 DOI: 10.1159/000345150.
• 29 Amet S, Launay-Vacher V, Clément O. et al. Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents. Invest Radiol 2014; 49: 109-115
• 30 Attari H, Cao Y, Elmholdt TR. et al. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology 2019; 292: 376-386 DOI: 10.1148/radiol.2019182916.
• 31 DGfN. Nephrogene Systemische Fibrose (NSF) Register. Im Internet (Stand: 30.10.2018): https://www.dgfn.eu/nsf-register.html
• 32 Becker S, Walter S, Witzke O. et al. The German registry for nephrogenic systemic fibrosis: findings from 23 patients. Clin Nephrol 2010; 73: 426-430 DOI: 10.5414/cnp73426.
• 33 Pasquini L, Napolitano A, Visconti E. et al. Gadolinium-Based Contrast Agent-Related Toxicities. CNS Drugs 2018; 32: 229-240 DOI: 10.1007/s40263-018-0500-1.
• 34 Costa AF, van der Pol CB, Maralani PJ. et al. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018; 69: 373-382 DOI: 10.1016/j.carj.2018.04.002.
• 35 Arzneimittelkommission der deutschen Ärzteschaft. Rote-Hand-Brief zu Gadolinium-haltigen Kontrastmitteln. 2018
• 36 Weinreb JC, Rodby RA, Yee J. et al. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021; 298: 28-35 DOI: 10.1148/radiol.2020202903.
• 37 Rodby RA. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 2008; 21: 145-149 DOI: 10.1111/j.1525-139X.2007.00405.x.
• 38 Gheuens Dea. Dialysability of Gadoteric Acid in Patients With End-Stage Renal Disease Undergoing Hemodialysis. 2014: 505-508
• 39 Murashima M, Drott HR, Carlow D. et al. Removal of gadolinium by peritoneal dialysis. Clin Nephrol 2008; 69: 368-372 DOI: 10.5414/cnp69368.
• 40 Schieda N, Blaichman JI, Costa AF. et al. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can J Kidney Health Dis 2018; 5 DOI: 10.1177/2054358118778573.
• 41 Reimer P, Vosshenrich R. Kontrastmittel in der Radiologie: Aktuelle Zulassungen, Empfehlungen und Sicherheitshinweise. Radiologe 2013; 53: 153-164 DOI: 10.1007/s00117-012-2429-6.